Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Systemic mTOR inhibitors

2 evidence topics · 2 sources

Sirolimus systematic review

“Clinically meaningful, long-term improvement (up to 3 years) was noted in 92% (46/50), mostly previously treated subjects.” (opens the source at this quote in a new tab)

“prospective, controlled trials are clearly needed” (opens the source at this quote in a new tab)

Sirolimus for pediatric head and neck lymphatic malformations: systematic review

“97 paediatric patients” (opens the source at this quote in a new tab)

“94 mild-to-moderate adverse events were reported.” (opens the source at this quote in a new tab)